Asset Details
Do you wish to reserve the book?
Cooperative development of antimicrobials: looking back to look ahead
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cooperative development of antimicrobials: looking back to look ahead
Do you wish to request the book?
Cooperative development of antimicrobials: looking back to look ahead
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cooperative development of antimicrobials: looking back to look ahead
2015
Overview
In this Science and Society article, Carl Nathan reviews historical collaborations between industry and academic instiutions that developed antimicrobials, and discusses similar strategies that have recently emerged to tackle the crisis of antimicrobial resistance.
As foundations and governments mobilize to tackle antimicrobial resistance (AMR), several experiments in academic–industrial collaboration have emerged. Here, I examine two historical precedents, the Penicillin Project and the Malaria Project of the Second World War, and two contemporary examples, the Tuberculosis Drug Accelerator programme and the Tres Cantos Open Lab. These and related experiments suggest that different strategies can be effective in managing academic–industrial collaborations, and that such joint projects can prosper in both multisite and single-site forms, depending on the specific challenges and goals of each project. The success of these strategies and the crisis of AMR warrant additional investment in similar projects.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Anti-Bacterial Agents - history
/ Anti-Bacterial Agents - therapeutic use
/ Anti-Infective Agents - history
/ Anti-Infective Agents - therapeutic use
/ Antimalarials - therapeutic use
/ Antitubercular Agents - history
/ Antitubercular Agents - therapeutic use
/ Drug Discovery - organization & administration
/ Drug resistance in microorganisms
/ Europe
/ Interinstitutional Relations
/ Malaria
/ Public-Private Sector Partnerships
/ Virology
